Vigmed Board makes additional proposals for the Annual General Meeting

Report this content

Bure Equity AB (publ), being the second largest shareholder in Vigmed with 10 % of the shares, has submitted a proposal to expand the Board from seven to eight members through the election of Philip Nyblaeus as a representative of Bure. Vigmed’s Board of Directors together with shareholders who represent more than 47 % of the total number of shares of the Company have expressed their support to this addition, therefore the proposal from the Board of Directors for the election of new Board members at the Annual General Meeting May 13, 2015 will be modified.

The proposal is within the current articles of association. The Board, in consultation with shareholders representing over 47% of the total shares, discussed the proposal and have decided to support it. For some time several major shareholders have expressed a wish that Bure would become more involved in Vigmed, as Bure possesses great expertise within the Company's area of business and also is a large shareholder. The proposal from Bure is therefore much appreciated.

In order not to burden the Company with additional costs through the increased number of Board members, the Company's Board of Directors has decided to propose to the General Meeting to adjust previously proposed fees: the Chairman’s fee would then receive an unchanged annual fee of SEK 150,000 whereas Board Members who not are employees of the Company should receive an annual fee of SEK 85,000.

Philip Nyblaeus has worked as an Investment Manager at AB Bure Equity since 2011. He has an MBA from Uppsala University and before joining Bure he worked at PwC Corporate Finance.

For further information contact:

Chairman of the board, Lennart Holm +46 70 630 8562 or CEO, Finn Ketler +46 42 600 5311

Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries and the associated risk of cross infections with blood-borne infectious diseases by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden, and has 20 employees. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has approximately 5 600 shareholders. Remium Nordic AB is the Company’s Certified Advisor.

Additional information about the company can be found on Vigmed’s website:


Documents & Links